NASDAQ$VERV
Verve Therapeutics Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Verve Therapeutics reported financial results and pipeline updates.
Verve Therapeutics reported a net loss of $48.4 million for Q4 2023, with cash, cash equivalents, and marketable securities totaling $624.0 million as of December 31, 2023, expected to fund operations into late 2026. The company made progress with its clinical programs, including VERVE-101, VERVE-102, and VERVE-201, and anticipates having three in vivo gene editing programs in the clinic in 2024.
- First human proof-of-concept data for in vivo base editing demonstrated in Heart-1 Phase 1b clinical trial of VERVE-101.
- Three clinical-stage programs targeting PCSK9 and ANGPTL3 are expected in 2024.
- IND clearance received from U.S. FDA for VERVE-101.
- Cash, cash equivalents, and marketable securities totaled $624 million, providing a cash runway into late 2026.
Headline financials
Revenue & EPS history
Verve Therapeutics · Revenue · Quarterly
$5.14M
Revenue by segment
Verve Therapeutics · $3.12M total across 1 segment · Q3 2023
- Collaboration Revenue$3.12M—100.0%
Forward guidance
Verve Therapeutics anticipates several milestones in 2024, including dosing the first patient in the U.S. in the VERVE-101 trial, completing enrollment in the Phase 1b trial of VERVE-101, initiating the Heart-2 Phase 1b trial for VERVE-102, and initiating a Phase 1b trial for VERVE-201.
Tailwinds
- Dose the first patient in the United States in the VERVE-101 trial.
- Complete enrollment in the ongoing Phase 1b trial of VERVE-101 and provide a data update.
- Initiate the Heart-2 Phase 1b trial for VERVE-102 targeting PCSK9 in the first half of the year.
- Initiate a Phase 1b trial for VERVE-201 targeting ANGPTL3 in the second half of the year.
- Have three in vivo gene editing programs in the clinic in 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q4 2023
-1.0%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-3.8%
Avg return
30 days after
47%
8 / 17 earnings
Positive
+24.4%
Q4 2023
Best reaction
-34.2%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2025 | +3.4% | +5.0% | +48.1% | |
| Q4 2025 | -1.7% | -2.9% | -16.3% | |
| Q3 2024 | +6.0% | +4.5% | +1.0% | |
| Q2 2024 | -12.1% | -20.8% | -1.6% | |
| Q1 2024 | +3.2% | +0.8% | -15.6% | |
| Q4 2023 | +24.4% | +12.7% | -8.2% | |
| Q3 2023 | +11.8% | +4.8% | -13.8% | |
| Q2 2023 | +2.6% | -9.9% | -28.0% | |
| Q1 2023 | -5.2% | -4.5% | -2.6% | |
| Q4 2022 | +7.0% | +3.0% | -20.8% | |
| Q3 2022 | -34.2% | -13.7% | -31.5% | |
| Q2 2022 | +17.5% | +31.2% | +47.0% | |
| Q1 2022 | -4.4% | +12.8% | +15.2% | |
| Q4 2021 | -20.1% | -4.3% | -19.7% | |
| Q3 2021 | -2.7% | -7.8% | -34.7% | |
| Q4 2020 | -1.4% | +5.5% | +7.5% | |
| Q2 2021 | -10.7% | -11.9% | +10.1% | |
| Q1 2021 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro